International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors

Abstract

Background: Sinonasal neoplasms, whether benign and malignant, pose a significant challenge to clinicians and represent a model area for multidisciplinary collaboration in order to optimize patient care. The International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors (ICSNT) aims to summarize the best available evidence and presents 48 thematic and histopathology-based topics spanning the field.

Methods: In accordance with prior International Consensus Statement on Allergy and Rhinology documents, ICSNT assigned each topic as an Evidence-Based Review with Recommendations, Evidence-Based Review, and Literature Review based on the level of evidence. An international group of multidisciplinary author teams were assembled for the topic reviews using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses format, and completed sections underwent a thorough and iterative consensus-building process. The final document underwent rigorous synthesis and review prior to publication.

Results: The ICSNT document consists of four major sections: general principles, benign neoplasms and lesions, malignant neoplasms, and quality of life and surveillance. It covers 48 conceptual and/or histopathology-based topics relevant to sinonasal neoplasms and masses. Topics with a high level of evidence provided specific recommendations, while other areas summarized the current state of evidence. A final section highlights research opportunities and future directions, contributing to advancing knowledge and community intervention.

Conclusion: As an embodiment of the multidisciplinary and collaborative model of care in sinonasal neoplasms and masses, ICSNT was designed as a comprehensive, international, and multidisciplinary collaborative endeavor. Its primary objective is to summarize the existing evidence in the field of sinonasal neoplasms and masses.

Keywords: adenocarcinoma; adenoid cystic carcinoma; adjuvant therapy; angiofibroma; biopsy; chemotherapy; concurrent; endoscopic endonasal approach; esthesioneuroblastoma; evidence-based medicine; head and neck cancer; head and neck oncology; immunotherapy; induction chemotherapy; inverted papilloma; lymphoma; margins; metastases; mucosal melanoma; nasopharyngeal carcinoma; neoadjuvant therapy; neuroectodermal carcinoma; neuroendocrine carcinoma; olfactory neuroblastoma; open approach; orbit; papilloma; quality of life; radiation; resectability; rhabdomyosarcoma; risk factors; sarcoma; sinonasal cancer; sinonasal malignancy; sinonasal neoplasm; sinonasal oncology; sinonasal papilloma; sinonasal tumor; sinonasal undifferentiated carcinoma; skull base; squamous cell carcinoma; surgery; surveillance; survival; survivorship.